Palatin reports Q2 EPS (12c) vs. (56c) last year
Pursuant to the completion of the sale of Vyleesi’s worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171M ...
Veru reports Q1 cont-op EPS (1c) vs. (8c) last year
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...